Regeneron Pharmaceuticals
Latest statistics and disclosures from Regeneron Pharmaceuticals's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NTLA, Adicet Bio, and represent 100.00% of Regeneron Pharmaceuticals's stock portfolio.
- Reduced shares in these 3 stocks: , Adicet Bio (-$7.6M), ADVM.
- Sold out of its positions in ADVM, ALNY.
- Regeneron Pharmaceuticals was a net seller of stock by $-643M.
- Regeneron Pharmaceuticals has $34M in assets under management (AUM), dropping by -95.17%.
- Central Index Key (CIK): 0000872589
Tip: Access up to 7 years of quarterly data
Positions held by Regeneron Pharmaceuticals consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Regeneron Pharmaceuticals
Regeneron Pharmaceuticals holds 2 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Intellia Therapeutics Common Stock (NTLA) | 98.5 | $33M | 3.7M | 8.99 |
|
|
| Adicet Bio Common Stock | 1.5 | $510k | -93% | 61k | 8.42 |
|
Past Filings by Regeneron Pharmaceuticals
SEC 13F filings are viewable for Regeneron Pharmaceuticals going back to 2024
- Regeneron Pharmaceuticals 2025 Q4 filed Feb. 6, 2026
- Regeneron Pharmaceuticals 2025 Q3 filed Nov. 7, 2025
- Regeneron Pharmaceuticals 2025 Q2 filed Aug. 1, 2025
- Regeneron Pharmaceuticals 2025 Q1 filed May 2, 2025
- Regeneron Pharmaceuticals 2024 Q4 filed Feb. 7, 2025